MXCT Share Price Performance
US$1.52
-2.87 (-65.38%)
77.2% undervalued intrinsic discount
US$6.68
Fair Value
Price US$1.52
AnalystConsensusTarget US$6.68
Fair ValueUS$6.68
Share Pricen/a
MaxCyte, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
MXCT Community Narratives
AN
Fair Value US$6.68 77.2% undervalued intrinsic discount
Upcoming Cell And Gene Therapy Milestones Are Expected To Transform Long Term Royalty Prospects
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Upcoming Cell And Gene Therapy Milestones Are Expected To Transform Long Term Royalty Prospects
Catalysts About MaxCyte MaxCyte provides electroporation-based cell engineering platforms and related services that enable the development and commercialization of advanced cell and gene therapies. What are the underlying business or industry changes driving this perspective?Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$6.68
77.2% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
22.43% p.a.
Profit Margin
15.5%
Future PE
93.27x
Price in 2028
US$8.41
Trending Discussion
Recently Updated Narratives
AN
Upcoming Cell And Gene Therapy Milestones Are Expected To Transform Long Term Royalty Prospects
Fair Value: US$6.68 77.2% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
MaxCyte, Inc. Key Details
About MXCT
- Founded
- 1998
- Employees
- 114
- CEO
- WebsiteView website
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
